In addition, 15 tumor mutations were identified in the high- and low-risk groups, and we demonstrated that the frequency of TP53 mutations was higher in the low-risk patients (high-risk: 40%, low-risk: 51%), whereas the high-risk patients had a greater frequency of KAS mutations (high-risk: 33%, low-risk: 22%, Figure 9A, 9B). This evidence concerns the gene TP53 and neoplasm.